KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Change in Cash (2016 - 2025)

Historic Change in Cash for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $92.9 million.

  • CRISPR Therapeutics AG's Change in Cash rose 13588.81% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 12011.45%. This contributed to the annual value of -$91.3 million for FY2024, which is 15157.48% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Change in Cash stood at $92.9 million, which was up 13588.81% from -$41.6 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Change in Cash ranged from a high of $521.8 million in Q2 2021 and a low of -$636.3 million during Q3 2021
  • Over the past 5 years, CRISPR Therapeutics AG's median Change in Cash value was -$42.6 million (recorded in 2021), while the average stood at -$46.7 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Change in Cash tumbled by 69529.89% in 2021, and later surged by 312698.76% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Change in Cash stood at -$88.5 million in 2021, then plummeted by 223.64% to -$286.3 million in 2022, then surged by 51.61% to -$138.5 million in 2023, then soared by 152.4% to $72.6 million in 2024, then grew by 27.96% to $92.9 million in 2025.
  • Its Change in Cash stands at $92.9 million for Q3 2025, versus -$41.6 million for Q2 2025 and -$63.1 million for Q1 2025.